
Biosidus Announces Promising Interim Results from Phase III Study on Agalsidase Beta for Fabry Disease
BUENOS AIRES, Argentina, April 16, 2025 (GLOBE NEWSWIRE) -- Biosidus, an Argentinean pioneer company in biotechnology research, development, and the production of high-quality biosimilars, has announced encouraging interim results from the Phase III SMILE1 …